This antibody binds and blocks the activation of the PD-1 receptor. The antibody is humanized, containing a human IgG4 Fc region with an engineered hinge region mutation (S228P) designed to prevent the exchange of IgG4 molecules. This antibody is equivalent to Nivolumab, which has been approved by the FDA for the treatment of melanoma and metastatic squamous non-small cell lung cancer.
Clonality
Monoclonal
Description
Humanized recombinant anti-PD-1 (IgG4) antibody with S228P mutation, expressed in HEK293 cells. This antibody has not been tested with other species.
assay conditions: Antibody was added to PD-1: PD-L1 (Biotinylated) binding assay at various concentrations. Assay was performed according to the protocol in BPS Cat. #72005 or #72006, respectively.
Specific activity: IC50 = 14 nM
Formulation
8 mM phosphate, pH 7.4, 110 mM NaCl, 2.2 mM KCl, and 20% glycerol.
Isotype
IgG4
Molecular Weight
Heavy Chain: 50 kDa, Light Chain: 25 kDa
Species
Human
Synonyms
PD-L1 Neutralizing Antibody, Programmed Cell Death 1 Ligand 1, PD1
Tag
None
Note
Avoid freeze/thaw cycles.
Uniprot
Q15116
Format
Aqueous buffer solution.
Purification
Protein A affinity chromatographyfrom HEK293 supernatants.
Shipping Temperature
-80°C (dry ice)
Storage Stability
Stable for at least 12 months at -80°C. Store diluted antibody with carrier protein (BSA 0.1 - 0.5%) at 4°C, stable for 2 weeks.